WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H572153
CAS#: 1357362-02-7
Description: Vafidemstat, also known as ORY 2001, is a lysine-specific histone demethylase (LSD1) inhibitor. Studies have shown LSD1 inhibitors to be effective in cancer suppression (i.e. breast and prostate cancer) as well as endometriosis.
Hodoodo Cat#: H572153
Name: Vafidemstat
CAS#: 1357362-02-7
Chemical Formula: C19H20N4O2
Exact Mass: 336.16
Molecular Weight: 336.400
Elemental Analysis: C, 67.84; H, 5.99; N, 16.66; O, 9.51
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ORY 2001; ORY-2001; ORY2001; Vafidemstat;
IUPAC/Chemical Name: 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine
InChi Key: XBBRLCXCBCZIOI-DLBZAZTESA-N
InChi Code: InChI=1S/C19H20N4O2/c20-19-23-22-18(25-19)11-21-17-10-16(17)14-6-8-15(9-7-14)24-12-13-4-2-1-3-5-13/h1-9,16-17,21H,10-12H2,(H2,20,23)/t16-,17+/m0/s1
SMILES Code: [H][C@@]1([C@@](NCC2=NN=C(N)O2)([H])C1)C(C=C3)=CC=C3OCC4=CC=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 336.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Hayward D, Cole PA. LSD1 Histone Demethylase Assays and Inhibition. Methods Enzymol. 2016;573:261-78. doi: 10.1016/bs.mie.2016.01.020. Epub 2016 Feb 23. Review. PubMed PMID: 27372757; PubMed Central PMCID: PMC5178825.
2: Sun Q, Ding D, Liu X, Guo SW. Tranylcypromine, a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis. Reprod Biol Endocrinol. 2016 Apr 9;14:17. doi: 10.1186/s12958-016-0154-0. PubMed PMID: 27062244; PubMed Central PMCID: PMC4826530.
3: Etani T, Suzuki T, Naiki T, Naiki-Ito A, Ando R, Iida K, Kawai N, Tozawa K, Miyata N, Kohri K, Takahashi S. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget. 2015 Feb 20;6(5):2865-78. PubMed PMID: 25605246; PubMed Central PMCID: PMC4413623.
4: Mino K, Nishimura S, Ninomiya S, Tujii H, Matsumori Y, Tsuchida M, Hosoi M, Koseki K, Wada S, Hasegawa M, Sasaki R, Murakami-Yamaguchi Y, Narita H, Suzuki T, Miyata N, Mizukami T. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2). Biosci Biotechnol Biochem. 2014;78(6):1010-7. doi: 10.1080/09168451.2014.910104. Epub 2014 Jun 13. PubMed PMID: 25036127.
5: Murray-Stewart T, Woster PM, Casero RA Jr. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids. 2014 Mar;46(3):585-94. doi: 10.1007/s00726-013-1485-1. Epub 2013 Mar 19. PubMed PMID: 23508577; PubMed Central PMCID: PMC3692581.
6: Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis. 2013 Jun;34(6):1196-207. doi: 10.1093/carcin/bgt033. Epub 2013 Jan 25. PubMed PMID: 23354309; PubMed Central PMCID: PMC3670252.
7: Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, Kirfel J, Waldmann H, Schüle R, Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012 Dec 1;131(11):2704-9. doi: 10.1002/ijc.27555. Epub 2012 Jun 28. PubMed PMID: 22447389.